NPO is one of the top Russian pharmaceutical companies and the largest national manufacturer of immunobiological preparations: vaccines, serums, specific immunoglobulins, growth media, allergens, probiotics.
NPO Microgen includes enterprises producing immunobiological preparations, whose history dates back to the beginning of the 20th century: NPO Virion in Tomsk, Immunopreparat in Ufa.
The main value of FSUE NPO Microgen of the Russian Ministry of Health is its employees, who help the company take the leading positions in the industry.
Today the company has more than 6,200 employees, including: 125 candidates of sciences, 15 doctors of sciences and 10 professors.
At the beginning of 2014, NPO Microgen brought to the aesthetic medicine market the first Russian botulinum neurotoxin type A – Relatox. At the end of 2014, we received positive feedback from doctors and customers. In 2015, the production of Relatox is planned to be increased by 3 times! The Ministry of Health has approved clinical studies to extend the indications of Relatox in neurology for children with cerebral palsy, and this means that upon completion of the studies the indications of Relatox will be extended, which repeatedly emphasizes the safety and efficiency of the Russian product whose quality is not inferior to that of foreign analogs.
Another promising line of business of NPO Microgen is bacteriophages: at present the company is the only Russian producer of this type of drugs. In 2014, a dysentery polyvalent bacteriophage in the liquid form was brought to the market. Previously, this drug was produced in tablets only. The new treatment and the way to prevent outbreaks of acute intestinal infections at the same time has become available to Russians. Given the efficacy and safety of the drug, it is in great demand. We plan to increase the profit from sales of bacteriophages at least by 1.5 times in 2015. This is not a random figure – the forecast is based on the market analysis.
Specialists of NPO Microgen have created the first Enterobacter bacteriophage drug in the world practice. It will help to treat acute intestinal diseases, infections of the biliary and urinary tracts, purulent skin lesions, meningitis, sepsis, hospital-acquired infections. We are planning to launch it in the consumer market in 2016.
And, of course, we pay great attention to vaccines that are included in the National Calendar of Preventive Vaccinations or will be included in its extended version.
NPO Microgen has prepared production sites to manufacture the first domestic thiomersal-free Td vaccine (low-dose adsorbed tetanus and diphtheria vaccine). This vaccine free from organic mercury compounds is identical to thiomersal-based preparations for its efficacy, safety, physical and chemical properties and complies with national and international requirements to the quality of vaccines. In addition, a thiomersal-free inactivated pertussis suspension has also been successfully registered. Tetanus toxoid, low-dose diphtheria toxoid, TDP and TDP-HepB vaccines free from this preservative are being prepared for registration.
The combined diphtheria, tetanus and pertussis (TDaP) vaccine, well known to all parents, has received a new component for the prevention of Hepatitis B and Hib and has become pentavalent. The new vaccine was developed in the Perm branch of NPO Microgen. At present, two associated pentavalent DTP-HepB-Hib vaccines containing the whole-cell pertussis vaccine (wP) and acellular pertussis vaccine (aP) are ready for clinical trials.
NPO Microgen has begun clinical studies of the combined measles-mumps-rubella (MMR) vaccine Vaktrivir.
The Ufa branch of NPO Microgen has developed and begun the production of the new influenza vaccine Sovigripp. The vaccine contains the adjuvant Sovidon (copolymer of N-vinylpyrrolidone and 2-methyl-5-vinylpyridine) instead of polyoxidonium used in similar vaccines. Sovidon is known to have immunomodulatory, detoxifying, antioxidant and membrane-protective properties due to its polymeric nature. Studies have shown that the preparation is almost non-toxic and non-pyrogenic (does not induce fever). The current capacity of the company allows production of up to 27 million doses of vaccines per year.